Julie Collins, MD, MedStar Georgetown University Hospital

home / authors / julie-collins,-md,-medstar-georgetown-university-hospital

Articles

Julie M. Collins, MD, MPH, of MedStar Health

Dr. Collins on the Rationale for CDK4/6 Inhibitors in ER+ Breast Cancer

Julie Collins, MD, MedStar Georgetown University Hospital
October 13th 2020

Julie M. Collins, MD, MPH, discusses the rationale for CDK4/6 inhibitors in endocrine receptor-positive breast cancer.

Read More

Precision Medicine in Metastatic Triple Negative Breast Cancer

Precision Medicine in Metastatic Triple Negative Breast Cancer

Sarah Sammons, MD, Duke Cancer Institute;Julie Collins, MD, MedStar Georgetown University Hospital;Kelly McCann, MD, PhD, Ronald Reagan UCLA Medical Center;Laura Spring, MD
September 16th 2020

Read More

HER2+ Early-Stage Breast Cancer: Peri-Operative Therapy

HER2+ Early-Stage Breast Cancer: Peri-Operative Therapy

Sarah Sammons, MD, Duke Cancer Institute;Julie Collins, MD, MedStar Georgetown University Hospital;Kelly McCann, MD, PhD, Ronald Reagan UCLA Medical Center;Laura Spring, MD
September 16th 2020

Read More

Metastatic HER2+ Breast Cancer

Metastatic HER2+ Breast Cancer

Sarah Sammons, MD, Duke Cancer Institute;Julie Collins, MD, MedStar Georgetown University Hospital;Kelly McCann, MD, PhD, Ronald Reagan UCLA Medical Center;Laura Spring, MD
September 16th 2020

Read More

Metastatic HR+ Breast Cancer

Metastatic HR+ Breast Cancer

Sarah Sammons, MD, Duke Cancer Institute;Julie Collins, MD, MedStar Georgetown University Hospital;Kelly McCann, MD, PhD, Ronald Reagan UCLA Medical Center;Laura Spring, MD
September 16th 2020

Read More

Latest Updated Articles

Sarwish Rafiq, PhD
Published: July 9th 2024 | Updated: July 10th 2024
Dr Rafiq on Novel Strategies for CAR T-Cell Engineering in Solid Tumors
Jens Hoeppner, FAChirg, FACS, MD
Published: June 2nd 2024 | Updated: June 3rd 2024
Perioperative Chemotherapy Prolongs OS vs Neoadjuvant Chemoradiation in Esophageal Cancer
Julia Rotow, MD, clinical director, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute; assistant professor, medicine, Harvard Medical School
Published: July 25th 2024 | Updated: July 27th 2024
Dr Rotow on the Impact of Biomarker Testing on NSCLC Treatment Outcomes
Joshua K. Sabari, MD, assistant professor, Department of Medicine, New York University Grossman School of Medicine; director, High Reliability Organization Initiatives, Perlmutter Cancer Center
Published: July 25th 2024 | Updated: July 27th 2024
Dr Sabari on Barriers to Biomarker Testing in NSCLC
5 KOLs are featured in this series.
Published: July 18th 2024 | Updated: July 27th 2024
Treatment Considerations and Patient Selection for CAR T-cell Therapy in R/R ALL
5 KOLs are featured in this series.
Published: July 18th 2024 | Updated: July 27th 2024
Expert Insights on ZUMA-3 Data Updates: 4-Year Follow-up and Real World Data